Introduction
============

During the past decade attempts were made to find a drug decreasing the high mortality in severe sepsis and septic shock. Recently, a trial showed a significant reduction in mortality under the application of drotrecogin alfa (activated) (Xigris; Eli Lilly, Bad Homburg, Germany) (recombinant human activated protein C \[APC\]). Severe thrombocytopenia might be a risk factor for serious bleeding under this therapy. The median plasma concentration of APC at steady state is 0.045 μg/ml. A previous study revealed an APC-dependent reduction of CD62P on the platelet surface exclusively after activation with recombinant tissue factor. However, the amounts of APC used were high, above steady-state concentrations (0.5--20 μg/ml), and the effect of APC in therapeutic concentrations on the expression of platelet receptors has not yet been studied systematically.

Objective
=========

To evaluate the influence of drotrecogin alfa (activated) on *in vitro*expression of platelet receptors at a therapeutic concentration.

Methods
=======

Citrated blood was drawn from healthy blood donors (*n*= 22, 45.5% male, age 38 ± 13 years \[mean ± SD\]). Exclusion criteria were smoking, diabetes and use of drugs interfering with platelet function. Blood samples were adjusted with APC to final concentrations of 0.045 μg/ml APC (group 1, therapeutic dose) and 0.225 μg/ml APC (group 2, fivefold therapeutic dose), respectively. The control group received no additional APC. To evaluate platelet reactivity, samples were activated with 5 μM thrombin-receptor-agonist-peptide-6 (TRAP-6; Bachem, Heidelberg, Germany) or 2.5 μM adenosine-di-phosphate (ADP; Sigma, Taufkirchen, Germany). Samples were incubated for 10 min at 37°C with fluorescence-labeled monoclonal antibodies (mAB) against CD62P (fluorescein isothiocyanate, FITC), CD41 (phycoerythrin \[PE\]), CD42b(PE), CD45(FITC) (all from Beckman-Coulter, Krefeld, Germany) or PAC-1(FITC) (Becton Dickinson, San Jose, CA, USA). Analyses were performed in a flow-cytometer (Epics XL; Beckman-Coulter). The mean fluorescence intensity was calculated for all mAB except CD45. After gating granulocytes, the percentage of CD45/41-positive complexes was counted. Both calculations were run using the WinMDI software. Statistics for intergroup differences were performed by one-way ANOVA.

Results
=======

APC in group 1 had no significant influence on platelet activation, with and without stimulation. In group 2, CD62P and CD45/41 showed a slight but nonsignificant decrease.

Conclusion
==========

This study demonstrates that therapeutic plasma concentrations of drotrecogin alfa (activated) have neither an influence on expression of platelet activation markers nor on platelet--granulocyte complexes *in vitro*. Thus, a disturbance of primary hemostasis seems unlikely.
